Business Context and Reporting Period
Company: BioTime, Inc. (Note: Metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Quarterly period ended June 30, 2001 (10-Q).
Business Stage: Development stage biomedical organization focused on synthetic plasma expanders (Hextend), blood volume substitutes, and organ preservation solutions (PentaLyte, HetaCool).
Key Partnership: Exclusive license with Abbott Laboratories to manufacture and sell Hextend in the U.S. and Canada.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2001 |
Six Months Ended June 30, 2001 |
Six Months Ended June 30, 2000 |
|---|---|---|---|
| Total Revenue | $29,958 | $62,653 | $13,119 |
| Net Loss | $(1,120,024) | $(2,071,763) | $(2,649,708) |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.18) | $(0.24) |
| Cash and Equivalents (End of Period) | $192,973 (as of June 30, 2001) | ||
| Total Current Liabilities | $830,561 (as of June 30, 2001) | ||
| Accumulated Deficit (Inception to Date) | $(29,208,007) |
Debt: $500,000 drawn on a revolving line of credit (converted to debenture in August 2001).
Liquidity: Cash balance decreased from $1.32 million (Dec 31, 2000) to $192,973 (June 30, 2001).
Material Changes vs. Prior Period
- Revenue Growth: Royalty revenue increased 306% for the three months ended June 30, 2001 ($29,958 vs. $7,387) and 378% for the six months ($62,653 vs. $13,119), driven by increased sales of Hextend by Abbott Laboratories.
- Expense Reduction: Research and Development (R&D) expenses decreased significantly, dropping 42% for the three months ($541,894 vs. $930,147) and 41% for the six months ($1.10M vs. $1.84M) compared to the prior year periods, due to reduced clinical trial spending.
- Operating Loss Improvement: Net loss narrowed for the six-month period to $2.07 million from $2.65 million in the prior year, despite higher General and Administrative (G&A) expenses due to increased personnel costs.
- Cash Burn: Net cash used in operating activities was $1.82 million for the six months ended June 30, 2001, compared to $2.84 million in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Financing & Covenants: In August 2001 (subsequent to period end), the company secured $3.35 million in debentures. This financing imposes strict covenants: quarterly operating cash payments are restricted to $450,000 plus cash revenues collected. No dividends or share repurchases are permitted until debt is repaid.
- Cost Cutting Measures: To conserve cash, the company initiated a compensation reduction program in August 2001, including salary deferrals and reductions ranging from 14% to 78% for employees and executives.
- Revenue Recognition Lag: Royalties are recognized in the quarter the sales report is received, not when sales occur. Q2 2001 sales royalties will be recognized in Q3 2001.
- Contract Termination: An exclusive license agreement with Horus B.V. (for international rights outside U.S./Canada/Japan) was terminated in August 2001 due to failure to meet obligations.
- Risks: Continued dependence on external financing; uncertainty of regulatory approvals for new products (PentaLyte, HetaCool); and reliance on Abbott's sales performance for Hextend.
Investor Verification Checklist
- Cash Runway: Verify if the $192,973 cash balance plus the $3.35M debenture proceeds are sufficient to meet the $450,000 quarterly operating cap and fund planned clinical trials.
- Debt Conversion: Confirm the terms of the August 2001 debenture conversion and the impact of the 10% interest rate on future cash flows.
- Abbott Sales Data: Monitor Abbott's reported sales of Hextend to validate the trajectory of royalty revenue, noting the one-quarter reporting lag.
- Regulatory Milestones: Track the status of the Canadian New Drug Submission for Hextend and the Phase I/II trials for PentaLyte and HetaCool.
- Equity Dilution: Assess the potential dilution from the 515,383 warrants issued with the debentures and existing stock options.